EVGN Evogene Ltd.
USHealthcareAs of 2026-07-10 14:24
Why EVGN matters now
Evogene Ltd. (EVGN) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.50 with +0.06% on the session and $4.3M in market capitalization; recent performance reads 1-month -29.42% and YTD -52.26%.
The latest financial table shown here is Q1 2026, with revenue of $334.0K, net income of $-5.9M, and EPS of $-0.60. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -260.3%.
The latest indexable market news headline is "Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $2.15; recent insider activity includes Ravzin Polina filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-2.06
P/S
2.52
EV/EBITDA
0.15
DCF Value
$-4.06
FCF Yield
-260.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
30.9%
Operating Margin
-757.2%
Net Margin
-639.4%
ROE
937.7%
ROA
-65.4%
ROIC
-100.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $334.0K | $-5.9M | $-0.60 |
| Q4 2025 | $314.0K | $-5.3M | $-0.61 |
| FY 2025 | $3.9M | $-8.5M | $-1.08 |
| Q3 2025 | $312.0K | $3.9M | $0.44 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$2.15
Target (Median)
$2.15
Target Range
$2.15 - $2.15
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
IL
Exchange
—
Beta
0.74
Evogene Ltd., along with its subsidiaries, operates as a computational biology firm. Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveraging its proprietary Computational Predictive Biology (CPB) platform. This platform, built on deep biological insights, big data analytics, and artificial intelligence, is engineered to digitally identify and strategically guide the creation of life-science solutions derived from microbes, small molecules, and genetic components. The company's operations are structured into three primary divisions: Agriculture, Human Health, and Industrial Applications. Within the Agriculture division, Evogene works on seed traits, agricultural chemicals, and biological products aimed at improving plant yields, with efforts spanning critical crops like corn, soybean, wheat, rice, and cotton. The Industrial Applications segment focuses on enhancing castor bean seeds for use as a raw material in various industrial applications. Meanwhile, the Human Health segment is dedicated to uncovering and developing human microbiome-based treatments for conditions including immuno-oncology, gastrointestinal disorders, and antimicrobial-resistant infections. Beyond these core areas, Evogene also delivers medical cannabis products. The company maintains a global presence, conducting operations in the United States, Israel, Brazil, and other international markets. It has forged key partnerships and licensing agreements with leading agricultural enterprises, such as BASF SE, Corteva, and Bayer. Additionally, its subsidiary, Canonic Ltd., collaborates with Cannbit Ltd. on the development of innovative medical cannabis offerings. Established in 1999, Evogene Ltd. is based in Rehovot, Israel.